摘要
洛沙坦的药动学特点及药物相互作用郭胜才冯友根（中国人民解放军第１１７医院杭州３１００１３）肾素－血管紧张素－醛固酮系统是重要的血压调节系统。临床上常用的血管紧张素转化酶抑制剂，能抑制血管紧张素Ⅰ转换成血管紧张素Ⅱ，使血管舒张，血压降低，具有一定的治疗...
出处
《中国医院药学杂志》
CAS
CSCD
北大核心
1998年第6期278-279,共2页
Chinese Journal of Hospital Pharmacy
参考文献12
-
1Man-wai LO ,Michael R Goldberg ,Jacqueline B MeCrea,et al. Pharmacokinetics of losartan,an angiotensin I receptor antagonist,and its active metabolite EXP3174 in humans. Clin pharmacol Ther, 1995,58 : 641.
-
2David D. Christ, Pancras C . Wong, Y. Nuncy Wong, Scott D. Hart, et al. The Pharmacokinetics and Pharmacodynamics of the Angiotensin I Receptor Antagonist losartan Potassium (Dup 753/Mk954) in the dog. The Journal of Pharmacology and Experimental Therapeutics, 1994, 268(3):119g.
-
3Alain Munato ,Yves Christen, Jurg Nussberger et al. Drug concentration response relationships in normal volunteers after aral administration of losatan. aa angiotensin I receptor antagonist. Clin Pharmacol Ther, 1992,51 : 513-21.
-
4David D.Christ,Human plasma protein binding of the an giotensin I receptor antagonist losartan potassium( Dup753/Mk954 ) and its pharmacologically active metabolite EXP3174. J Cliu Pharmacol, 1995,35:515--20.
-
5Michael R. Goldberg,Man Wai Lo,Paul J. Deutsch ,Sussn E.Wilson et al. Pheaobarbital minimally alters plasma concentrations of losartan and its active metabolite EXP3174.Clin Pharmacol Ther, 1996,59:268.
-
6M-W Lo, S Shahintar, CI Furtek, et al. Pharmacokinetics of losartan (Mk 954/Dup753) in patients with renal insufliciency.Clin Pharmacol Ther,1993,53(2):160.[Abstract].
-
7DJ Kazierad,DE Martin, D Teneyo,et al. Fluconazole significantly alters the pharmacokinetics of losartan but not eprosartan, Clin Pharmacol Ther, 1997, 61 (2): 203. [Abstract].
-
8KM Williamson,JH Pattersdon Ja Pieper. RH McQueen,et al, Effects of erythromycin or rifampin on steady state losartan pharmacokinetics in healthy volunteers. Clin Pharmacol Ther, 1997,61 (2) :202. [Abstract].
-
9Kong AN,Tomasko-L,Waidmaa-SA,et al. Losartan does not affect the pharmaeokinetics and pharmacodynamics of warfarin. J Clin Pharmacol, 1995,35 ( 10 ) : 1008.
-
10Beth A, Soffer,Jackson T. Wright, Jr, J.Howard Pratt,Btian Wiens, et al. Effects of losartan on a Background of hydrochlorothiazide in patients iwth hypertension, hypertension 1995,26:112.
同被引文献25
-
1黄祥,普文英.华法令和阿司匹林联合用药的临床观察[J].中国医院药学杂志,1984(3):16-18. 被引量：2
-
2吴德政,鲍云华,宋廷惠,陈学东,吴新民,李积德,王岩,刘保卫,何志嵩,周利群,乔歧禄.在330例疼痛病人中阿司匹林──可待因片的随机双盲对照临床试验[J].中国临床药理学杂志,1995,11(4):193-199. 被引量：4
-
3孙定人 王士凡 等.药物不良反应（第二版）[M].北京:人民卫生出版社,1996.476.
-
4孙定人 王士凡 张小明.药物不良反应(第二版)[M].北京：人民卫生出版社,1996.238.
-
5国家药典委员会.临床用药须知(第2版)[M].北京：化学工业出版社,2000.153.
-
6陈文 沈百余 杨毓瑛.合理用药分析200例(第二册)[M].上海：科学技术出版社,1990.77.
-
7田军.消化系统疾病[J].国外医学：内科学分册,1998,25(12):537-537.
-
8范琪慧.小剂量阿司匹林预防妊娠高血压综合征71例分析[J].杭州医学高等专科学校学报,2000,21(3):176-176.
-
9陈文 沈百余 杨毓瑛.合理用药分析200例(第二册)[M].上海:上海科学技术出版社,1990.77.
-
10Stojic D. Effects of captoprit and bradykinin on chrada tympaniduced salivation in cat[J]. Eur J Oral Sci, 1999, 107(1);21-24.
-
1段宝桂,邹庆平.血管紧张素Ⅱ受体拮抗剂—洛沙坦[J].山东医药工业,1997,16(4):24-25.
-
2孙石磊,刘章锁,张明轩,葛秀峰.福辛普利联合洛沙坦治疗提高对大鼠糖尿病肾病的疗效[J].中华内分泌代谢杂志,2002,18(4):278-279. 被引量：1
-
3宋丽雅,杨曜荣.洛沙坦治疗原发性高血压60例疗效观察[J].山东医药,2005,45(13):53-54. 被引量：1
-
4李晓勤.洛沙坦的药理和临床应用[J].山西临床医药,1998,7(3):183-184.
-
5揭荣荣,朱智明,石湘芸.洛沙坦等血管紧张素受体拮抗剂的研究进展[J].人民军医,1999,42(11):657-659.
-
6王寅,叶荣,李端阳.血管紧张素受体拮抗药洛沙坦研究进展[J].医学信息（医学与计算机应用）,2001,14(5):290-291.
-
7崔成红.洛沙坦改善老年高血压患者的记忆功能[J].化学医药工业信息,2004(7):39-40.
-
8范济明,秦可利.新型降压药—血管紧张素Ⅱ受体拮抗剂[J].军队医药,2000,10(1):54-56.
-
9常冰玲,周红梅.洛沙坦治疗高血压并肾功能异常的临床观察[J].河南实用神经疾病杂志,2002,5(2):79-80.
